Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

G Protein-coupled Receptors01:15

G Protein-coupled Receptors

11.0K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.0K
GPCR Desensitization01:12

GPCR Desensitization

5.7K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining the Intestinal eCBome and Oxylipin Signaling Systems in a TDP-43 Mouse Model of Frontotemporal Dementia.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy.

Neuropharmacology·2025
Same author

Relevance of a peripheral site of action outside the brain-blood barrier for the beneficial effects of CB<sub>2</sub> receptor activation in experimental ALS in male mice.

Cell communication and signaling : CCS·2025
Same author

Ageing, Neurodegeneration and the Endocannabinoid System.

Current topics in behavioral neurosciences·2025
Same author

Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Neurodegenerative Diseases: Pathogenesis and Preclinical Models for Translational Drug Discovery.

Toxicologic pathology·2025

Related Experiment Video

Updated: May 23, 2025

Monitoring GPCR-&#946;-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

6.8K

Development of Novel Neuroprotective Agents Targeting GPCR Using in Vitro Assays.

María Gómez-Cañas1,2,3, Carmen Rodríguez-Cueto1,2,3, Javier Fernández-Ruiz1,2,3

  • 1Instituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.

Methods in Molecular Biology (Clifton, N.J.)
|March 11, 2025
PubMed
Summary

This study details drug development for cannabinoid receptors (CB1 and CB2), focusing on compound affinity and signaling pathways. Research explores therapeutic potential for neurodegenerative diseases by modulating the endocannabinoid system.

Keywords:
Cannabinoid receptorsCompetition binding assaysDrug discoveryGPCRsIn vitro functional activity determinationIn vitro neuroprotection assays

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K
Characterization of G Protein-coupled Receptors by a Fluorescence-based Calcium Mobilization Assay
11:49

Characterization of G Protein-coupled Receptors by a Fluorescence-based Calcium Mobilization Assay

Published on: July 28, 2014

40.0K

Related Experiment Videos

Last Updated: May 23, 2025

Monitoring GPCR-&#946;-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

6.8K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K
Characterization of G Protein-coupled Receptors by a Fluorescence-based Calcium Mobilization Assay
11:49

Characterization of G Protein-coupled Receptors by a Fluorescence-based Calcium Mobilization Assay

Published on: July 28, 2014

40.0K

Area of Science:

  • Pharmacology and Drug Discovery
  • Neuroscience
  • Molecular Biology

Background:

  • G protein-coupled receptors (GPCRs), particularly cannabinoid receptors CB1 and CB2, are key drug targets.
  • Understanding receptor interactions beyond G proteins, like with β-arrestins, is crucial for developing selective drugs.
  • The endocannabinoid system (ECS) plays a vital role in neuroprotection, offering therapeutic avenues for neurodegenerative diseases.

Purpose of the Study:

  • To illustrate the drug development process for GPCRs, using cannabinoid receptors as a specific example.
  • To highlight methods for characterizing novel compounds targeting CB1 and CB2 receptors.
  • To explore the therapeutic potential of modulating the ECS for neurodegenerative conditions.

Main Methods:

  • Binding competition assays to assess compound affinity for CB1 and CB2 receptors.
  • Intracellular signaling analysis, including [35S]-GTPγS binding assays to evaluate G-protein activation.
  • In vitro cell line models and toxin-induced neurodegenerative disease mimics to test therapeutic efficacy.

Main Results:

  • Established methods for evaluating compound affinity and functional activity at cannabinoid receptors.
  • Demonstrated the importance of assessing biased agonism for selective pathway activation.
  • Utilized in vitro models to investigate the neuroprotective effects of cannabinoid receptor modulators.

Conclusions:

  • Drug discovery for GPCRs requires comprehensive assessment of affinity, functionality, and physiological impact.
  • Targeting the ECS offers a promising strategy for treating neurodegenerative diseases by mitigating neuroinflammation, excitotoxicity, and oxidative stress.
  • Characterizing compound interactions with cannabinoid receptors is essential for developing effective therapeutics.